Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Magrolimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Garetosmab, an antibody targeting Activin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cobolimab, an antibody targeting TIM-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cendakimab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Apamistamab, an antibody targeting PTPRC.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abelacimab, an antibody targeting Factor XI.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ziltivekimab, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tifcemalimab, an antibody targeting BTLA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sasanlimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rosopatamab, an antibody targeting PSMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Feladilimab, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tozorakimab, an antibody targeting IL-33.